Arrowhead Research Corporation

ARWRNASDAQ • USD
ThemeGenomics & Precision Med.›RNA Therapeutics
88.88 USD
↗ 2.15 (2.48%)AT CLOSE (11:59 AM EDT)
88.87
↘ 0.02 (0.02%)
POST MARKET (AS OF 07:30 PM EDT)
Post Market
AS OF 07:30 PM EDT
88.87
↘ 0.02 (0.02%)
🟢Market: OPEN

Arrowhead Research Corporation (ARWR) is currently trading at $88.87. Our models show a "Strong Buy" technical signal alongside a "Neutral" fundamental rating. Notable factors include a robust Altman Z-Score, negative Return on Equity, a bullish Golden Cross on the moving averages and bullish moving average alignment. Valuation-wise, the stock is priced at a premium — multiples like P/E and EV/EBITDA sit above sector averages.

Technical & fundamental data as of Aug 25, 2026.

Open?$88.00
High?$90.21
Low?$87.00
Prev. Close?$86.73
Volume?982.0K
Avg. Volume?1.7M
VWAP?$88.71
Rel. Volume?0.56x
Bid / Ask
Bid?$81.70 × 100
Ask?$92.67 × 100
Spread?$10.97
Midpoint?$87.19
Valuation & Ratios
Market Cap?12.3B
Shares Out?140.9M
Float?135.6M
Float %?96.2%
P/E Ratio?N/A
P/B Ratio?26.32
EPS?-$2.27
Dividend?0.31%
Ex-Dividend?N/A
News
Profile
Arrowhead Pharmaceuticals Inc is a commercial-stage pharmaceutical company. It is focused on the development of medicines for diseases associated with genetic abnormalities or protein overproduction. The company develops potential RNAi therapies designed to inhibit the expression of genes known to trigger diseases. Its portfolio includes potential drugs targeting Cardiometabolic, Neuromuscular, Pulmonary, Liver, and other diseases. The company also develops RNAi products and clinical candidates designed to target different cell types within the body.
Themes
Healthcare - Genomics & Precision Medicine›RNA TherapeuticsBiotech - Drug Development›Rare Disease Therapeutics
Employees
711
Market Cap
12.3B
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.arrowheadpharma.com
Listed
1995-02-01
Address
177 E COLORADO BLVD
PASADENA, CA 91105
Phone: 626-696-4702
Technical OutlookStrong Buy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+2/3)
Medium-Term (Wave)?▲ Bullish(+1/3)
Short-Term (Ripple)?▲ Bullish(+3/3)
MA Alignment?Golden Alignment
Full Technical Analysis →
Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?
23
Z-Score?
91
Momentum?
48
Short Sent.?
42
Piotroski F-Score?3/9Weak
Altman Z-Score?3.94Safe
Confidence?63%Moderate
Full Fundamental Analysis →
Short InterestHigh
Short % of Float?6.79%Elevated
Short Interest?9.2M
Days to Cover?7.8
Free Float135.6M
Avg Daily Volume1.2M
Settlement Date2026-08-14
Financial Health
Current Ratio?5.90Strong
Quick Ratio?5.90Strong
Cash Ratio?0.19Low
Debt/Equity?1.86High
ValuationRICHLY VALUEDvs 1 peers + S&P 500
Score
50/100
P/E?
N/A▾
P/B?
Peers
100
S&P
3
26.32HIGH▾
P/S?
Peers
100
S&P
3
18.30HIGH▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-65.1CHEAP▾
EV/Sales?
Peers
100
S&P
3
19.51HIGH▾
Returns & Efficiency
ROE?
S&P
3
-68.7%WEAK▾
ROA?
S&P
3
-15.2%WEAK▾
Cash Flow & Enterprise
FCF?$-75111000
Enterprise Value?$13.1B
Fundamentals ratios updated end of day
MarketsMoversWatchlist